Compare CCS & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCS | PVLA |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2014 | 2013 |
| Metric | CCS | PVLA |
|---|---|---|
| Price | $62.57 | $138.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $64.80 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 221.6K | 154.1K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ 52.62 |
| EPS | ★ 2.09 | N/A |
| Revenue | ★ $4,117,816,000.00 | $42,810,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.84 | $104,350.18 |
| P/E Ratio | $29.67 | ★ N/A |
| Revenue Growth | N/A | ★ 65.28 |
| 52 Week Low | $47.28 | $59.16 |
| 52 Week High | $76.00 | $161.38 |
| Indicator | CCS | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 38.77 |
| Support Level | $57.96 | $135.68 |
| Resistance Level | $65.78 | $143.76 |
| Average True Range (ATR) | 1.68 | 6.17 |
| MACD | 0.25 | -1.20 |
| Stochastic Oscillator | 65.49 | 8.57 |
Century Communities Inc is engaged in the development, design, construction, marketing and sale of single-family attached and detached homes. The company builds and sells homes under its Century Communities and Century Complete brands. Its reportable segments for homebuilding operations are: i) West (California and Washington) ii) Mountain (Arizona, Colorado, Nevada and Utah), iii) Texas, iv) Southeast (Florida, Georgia, North Carolina, South Carolina and Tennessee), v) Century Complete (Alabama, Arizona, Florida, Georgia, Indiana, Kentucky, Michigan, North Carolina, and South Carolina). The company's other reportable segments include: Financial Services and Century Living. The company derives the majority of its revenue from the sale of new homes in the Mountain segment.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.